Opaleye Management Inc., 10% Owner at Grace Therapeutics, Inc. (GRCE), bought 15,229 shares at $2.10 ($32K) on 2026-09-08, disclosed to the SEC on 2026-09-10.
Opaleye Management Inc. executed a $19,700 purchase of 9,393 shares at $2.10, marking the largest insider purchase in the company's history. This significant accumulation by a major holder suggests confidence in the stock's current valuation despite recent sector volatility.
The stock is trading at $2.12, down 1.85% over the last 5 days but up 0.95% over the last 30 days. It is currently 17.51% below its 52-week high of $2.57 and 14.59% above its 52-week low of $1.85.
Insiders have been net buyers over the past year, as noted by Simply Wall St. on November 1, 2025, indicating sustained institutional interest. Additionally, the company faces scrutiny regarding its cash burn rate, with Simply Wall St. highlighting this concern on April 4, 2026.
The stock is currently trading at a negative forward P/E of -4.87, suggesting the market anticipates continued losses. Furthermore, the company's short interest represents 8.68% of the float, indicating a notable level of skepticism among traders.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.10 | 9,393 | $20K | 61.8% |
| 2 | $2.09 | 5,836 | $12K | 38.2% |
| Total | $2.09 avg | 15,229 | $32K | 100% |
| Filing → |
| GRCE | BUY | 2026-10-01 | $16K | — | Filing → |
| GRCE | BUY | 2026-09-23 | $32K | — | Filing → |
| ACOG | BUY | 2026-09-16 | $1.1M | — | Filing → |